1 / 6

Supplementary Fig. 1. Treatment of VEGF-C with the human acute myeloid leukemic cell line,THP-1,

1B. 1A. 1D. 1C. Supplementary Fig. 1. Treatment of VEGF-C with the human acute myeloid leukemic cell line,THP-1,

keena
Download Presentation

Supplementary Fig. 1. Treatment of VEGF-C with the human acute myeloid leukemic cell line,THP-1,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 1B 1A 1D 1C Supplementary Fig. 1. Treatment of VEGF-C with the human acute myeloid leukemic cell line,THP-1, induced angiogenesis in vitro. (A and B) Treatment of THP-1 cells with 100 ng/ml of VEGF-C for 48 h and the CM was collected for HUVECs migration and tube formation assay. (C and D) VEGF-C did not induce proliferation and tube formation of HUVECs directly.HUVECs were treated with 100 ng/ml of VEGF-A, VEGF-C, or 0.1% FBS for 24, 48, and 72 h. Proliferation of HUVECs were measured by MTS assays (C). Pretreatment of the collected CM with histidine Ab for 24 h to immunodeplete histidine tag VEGF-C and showed comparable effects on tube formation with CM without VEGF-C immunodepletion (D).Lines or columns, means of three independent experiments; bars, SE. #, P < 0.01 as compared with the vehicle control group.

  2. 2B 2A Supplementary Fig. 2. Effects of COX-2 inhibitors, NS398 and indomethacin, on VEGF-C- induced angiogenesis in vitro. (A and B) THP-1 cells were pretreated with 10 mM NS398 or indomethacin for 30 min before incubation with 100 ng/ml of VEGF-C for 48 h, then the CM was collected for tube formation and HUVEC migration assay. Columns, means of three independent experiments; bars, SE. *, P < 0.05; **, P < 0.01 as compared with the VEGF-C treatment group.

  3. 3A 3B Supplementary Fig. 3. VEGF-C and VEGF-A upregulate COX-2 expression in human acute myeloid leukemic cells. (A)COX-2 mRNA and protein expression were upregulated in a time-dependent fashion after VEGF-C (100 ng/ml) treatment, peaking at 8 and 48 h in 2 human acute myeloid leukemic cells, U937 and HL60. (B) COX-2 protein expression was upregulated in a time-dependent fashion after VEGF-A (50 ng/ml) treatment, peaking at 24 h in THP-1, U937, and HL60 cells.

  4. Supplementary Fig. 4. Involvement of EP2 and EP4 receptors in the collected CM-induced tube formation. HUVECs tube formation ability of CM collected from VEGF-C-treated THP-1 after pretreatment of HUVECs with 3 mM AH6809 (EP2 antagonist), 30 mM AH23848 (EP4 antagonist), or 3 mM AH6809+30 mM AH23848 for 30 min. Columns, means of three independent experiments; bars, SE. **, P < 0.01 as compared with the VEGF-C treatment group.

  5. Supplementary Fig. 5. Similar localization of VEGF-C and COX-2. Immunohistochemical analysis of serial sections of bone marrow specimens from a representative patient with diagnosed AML shows identical coexpression and localization of VEGF-C and COX-2. Original magnification ×400.

  6. Supplementary Table 1. Primers used to perform RT-PCR of the respective target genes

More Related